Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XL020
- Development stage
- Preclinical
- Lead developer
- XL-protein
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
XL020 is a long-acting recombinant human growth hormone (hGH) analog being developed by XL-protein for the treatment of growth hormone deficiency. The drug is engineered using XL-protein's proprietary PASylation technology, which involves the genetic fusion of hGH with a bulky, hydrophilic, and uncharged polypeptide sequence consisting of Proline, Alanine, and Serine (PAS). This modification increases the protein's hydrodynamic volume, thereby reducing renal clearance and extending its plasma half-life. XL020 functions as an agonist of the growth hormone receptor (GHR), stimulating the production of insulin-like growth factor 1 (IGF-1) and promoting linear growth and metabolic regulation. It is currently in preclinical development as a potential long-acting alternative to daily hGH injections.
- Other names
- PAS-hGHPASylated hGH
02
Targets
GHR (Growth hormone receptor)
Beyond the preview
Go deeper on XL020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XL020.